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1044Soluble Tumor Necrosis Factor Receptor: Enbrel
(Etanercept) for Subacute Pulmonary Dysfunction
Following Allogeneic Stem Cell Transplantation
Gregory A. Yanik,1,2 Shin Mineishi,2 John E. Levine,1,2 Carrie L. Kitko,1 Eric S. White,2,3
Mark T. Vander Lugt,1 Andrew C. Harris,1 Thomas Braun,4 Kenneth R. Cooke5Subacute lung disease, manifested as either obstructive (OLD) or restrictive (RLD) lung dysfunction, is a com-
mon complication following allogeneic stem cell transplantation. In each case, therapeutic options are lim-
ited, morbidity remains high, and long-term survival is poor. Between 2001 and 2008, 34 patients with
noninfectious, obstructive (25) or RLD restrictive lung dysfunction (nine) received etanercept (Enbrel,
Amgen Inc.) 0.4 mg/kg/dose, subcutaneously, twice weekly, for 4 (group A) or 12 weeks (group B). Cortico-
steroids (if present at study entry) were kept constant for the initial 4 weeks of therapy and then tapered as
tolerated. Thirty-one of 34 (91%) subjects were evaluable for response, and 10 (32%) met primary response
criteria. There was no difference in response based on the duration of treatment (29% group A versus 35%
group B; P 5 .99), the presence of RLD or OLD (33% versus 32%; P 5 .73), or the severity of pulmonary
disease at study onset. Estimated 5-year overall survival rates following therapy were 61% (95% confidence
interval, 46%-80%) for all subjects and 90% (95% confidence level, 73%-100%) for the 10 who met the pri-
mary response criteria. Five-year survival estimates for subjects treated with RLD was 44%, compared with
67% for those treated for OLD (P 5 .19). Etanercept was well tolerated, with no bacteremia or viremia
observed. Pathogens were noted on posttherapy bronchoalveolar lavage in two cases. These data support
the development of expanded clinical trials to study etanercept as a therapeutic agent for subacute lung injury
after allogeneic stem cell transplantation.
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diseaseINTRODUCTION
Noninfectious lung injury is a frequent and severe
complication of allogeneic stem cell transplantation
(SCT), both in the acute and subacute setting. In the
acute setting, a diffuse interstitial process termed1Blood and Marrow Stem Cell Transplantation Program,
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ated by the production of inflammatory cytokines and
associated with high mortality rates (.50%) [1-3].
Subacute lung injury, on the other hand, typically
presents in patients over 100 days posttransplantation
and is associated with significant morbidity and
mortality within the first 1 to 2 years following SCT.
Subacute lung injury has been well described and
may present as obstructive (OLD) or restrictive
(RLD) lung dysfunction [4-11].
OLD is characterized by enhanced airflow
resistance upon expiration, reflecting narrowing or
destruction of smaller airways and terminal bronchi-
oles. Commonly associated with the occurrence of
chronic graft-versus-host disease (cGVHD), obtruc-
tive defects have been reported in 2% to 25% of
allogeneic SCT recipients [4,10-12] Bronchiolitis
obliterans remains the most common histopathology
associated with OLD. The clinical course is
variable, ranging from a gradual decline in lung
function over several years to a rapid pulmonary
deterioration over a fewmonths. Responses to standard
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usually resulting in preservation of, instead of
improvement in, existing lung function [13,14].
RLD is associated with reductions in forced vital
capacity (FVC), total lung capacity (TLC), and carbon
monoxide diffusion capacity (DLCO). Restrictive
defects are more frequent than obstructive changes
following allogeneic SCT, with an incidence of
20% to 45% reported [6,8,12,15]. In comparison to
OLD, restrictive defects typically present earlier, are
more frequent following conditioning regimens with
total-body irradiation, and have been found in associ-
ation with the development of both acute (aGVHD)
and cGVHD [16,17]. Similar to OLD, therapeutic
intervention often stabilizes, without significantly
improving respiratory function.
Over the past several years, preclinical data gener-
ated in our laboratory using murine transplantation
models indicate that two distinct, but interrelated
pathways of immune-mediated lung injury may exist:
one driven by soluble inflammatory cytokines and
the other by host antigen-specific T cell effectors.
Both pathways can target lung tissue, resulting in in-
flammation and pulmonary injury. Specifically, pre-
clinical data have revealed a critical role for tumor
necrosis factor-alpha (TNF-a) in the development
of IPS after allogeneic SCT [18,19], and these
laboratory insights have formed the foundation for
completed and ongoing clinical trials [20].
In contrast to acute lung injury, the pathophysi-
ology of subacute lung injury is less clearly defined.
The development of OLD is characterized by bronchi-
olar leukocyte recruitment leading to fibrinous-
obliteration of the small airways [10,21-23]. The
mechanism of injury likely involves injury to the
bronchiolar epithelium followed by an on-going in-
flammatory response and dysregulated repair [24].
The severity of the injury parallels the duration of
this inflammatory response. Similarly, the pathogene-
sis of RLD also appears to involve a chronic inflamma-
tory process in the lung interstitium, with interactions
between cytokine, chemokine, and cellular effectors
[24]. Bronchoalveolar lavage (BAL) fluid from patients
with bronchiolitis obliterans syndrome (BOS) follow-
ing lung allograft transplantation reveals elevations
in interleukin (IL)-1ra, IL-8, transforming growth
factor-beta (TGF-b), and monocyte chemotactic
protein-1 (MCP-1), all of which have been implicated
in other fibroproliferative processes [25-28]. Similarly,
elevations of TNF-a and TGF-b have been shown to
play a critical role in models of interstitial lung
disease and fibrosis [28-30].
Based on these findings, we initiated a clinical trial
employing a TNF-a binding agent, etanercept (En-
brel, Amgen Inc., Thousand Oaks, CA) for the treat-
ment of patients with noninfectious, subacute lung
injury following allogeneic SCT. Etanercept is asoluble dimeric protein consisting of two soluble p75
TNF receptors fused to the Fc portion of a type I im-
munoglobulin molecule [31-34]. The agent is FDA
approved for the treatment of rheumatoid arthritis
[35-38] and has shown efficacy and safety in clinical
trials for the treatment of aGVHD and cGVHD and
IPS [20,39,40]. We have now examined its potential
role in the treatment of subacute lung injury
following allogeneic SCT.MATERIALS AND METHODS
Patients
Study subjects were recruited from the Blood
and Marrow Stem Cell Program at the University of
Michigan Medical Center between 2001 and 2008,
all subjects having received an allogeneic SCT at least
100 days before study entry. Eligible subjects were
$6 years in age, with evidence of subacute, nonin-
fectious lung injury (OLD or RLD) based on abnor-
malities observed on pulmonary function tests
(PFTs). Patients were excluded if an active infection
was noted at the time of study entry, based on cultures
obtained from BAL fluid, blood, and urine. Patients
requiring inotropic blood pressure support or those
patients exhibiting clinical or echocardiographic signs
of left ventricular dysfunction were also excluded. The
study was approved by the University of Michigan
institutional review board, and all subjects provided
informed consent/assent before initiation of study
therapy.
Study Design
The diagnosis of subacute noninfectious lung in-
jury (Table 1) was based on the presence of the follow-
ing three criteria: (1) abnormal pulmonary function
tests, (2) clinical findings, and (3) absence of lower re-
spiratory tract infection based on negative BAL fluid or
lung biopsy cultures for infectious pathogens. Subjects
with subacute lung injury were stratified as having
either RLD or OLD based on the predominant
respiratory pattern. Restrictive lung defects were
defined by TLC and FVC #80% predicted, with
a .15% decline from the pretransplantation values.
Obstructive lung defects were defined by both the
FEV1 and FEV1/FVC, with the requirement for
a FEV1\80% predicted (and FEV1/FVC\75% pre-
dicted), with .15% decline in FEV1 from the pre-
transplantation value. Postbronchodilator values for
FEV1 were used if available. The date of diagnosis of
subacute lung injury was determined by the date of
the initial PFT that met the above criteria.
The 2005 National Institutes of Health (NIH)
consensus criteria for BOS were applied prospectively
to those subjects with OLD enrolled after 2005 [41].
Pulmonary function parameters for OLD were
Table 1. Subacute Lung Injury—Required Study Criteria
1. Clinical symptoms:
a. Cough, wheezing, or dyspnea on exertion or
b. Oxygen saturation #93% on room air.
2. Abnormal pulmonary function tests:
>15% decline from pretransplantation value, plus
a. Restrictive disease: FVC <80% predicted, OR
b. Obstructive disease: FEV1 <80% with FEV1/FVC <75% predicted
3. Absence of lower respiratory tract infection
a. Negative bronchoalveolar lavage or
b. Negative transbronchial or surgical lung biopsy (if performed).
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tion Scoring (LFS) system [41]. Lung function scores
were determined individually for FEV1 and DLCO,
with $80% 5 1, 70% to 79% 5 2, 60% to 69% 5
3, 50% to 59% 5 4, 40% to 49% 5 5, and\40% 5
6, based on % predicted spirometric values. The
FEV1 scores were summated with the DLCO score,
to determine an overall LFS score.
All eligible subjects were evaluated by BAL,
high-resolution computed tomography, and complete
PFTs before study therapy (Figure 1). Transbronchial
biopsies were not required but were considered on a
per-subject basis. Upon completion of study therapy,
subjects underwent repeat evaluation, including BAL,
PFTs, chest high-resolution computed tomography,
and serologic studies. In addition, PFTs and serologic
studies were repeated 28 days after study completion.
Subjects were treated with etanercept for either 4
weeks (group A) or 12 weeks (group B). Group
assignment was stratified by year of study entry. Group
A consisted of subjects treated between 2001 and 2002,
whereas group B subjects were treated from 2003 to
2008. Supportive care measures for both group A
and B were similar, except for the introduction of
voriconazole as antifungal prophylaxis in subjects
treated after 2005.Bronchoalveolar lavage
Patients were required to undergo BAL before
study enrollment and at the end of therapy. Assessment
of the pre- and posttherapy BAL fluid included GramEtanercept Therapy 
(Weeks 1-4) 
Posttherapy (Week 8) 
PFT
Pretherapy
BAL, PFT
End of Therapy (Week 4) 
BAL, PFT
Group A Group B
Etanercept Therapy 
(Weeks 1-12) 
End of Therapy (Week 12) 
BAL, PFT
Posttherapy (Week 20) 
PFTs
Figure 1. Study schema.stain; quantitative bacterial culture; viral cultures for
respiratory syncytial virus, parainfluenza, adenovirus,
influenza A and B, herpes simplex virus, and cytomeg-
alovirus (CMV); stains for fungi; fungal and mycobac-
terial cultures; stains for acid-fast bacilli, fungi, and
Pneumocystis jiroveci pneumonia; and polymerase chain
reaction for Pneumocystis jiroveci pneumonia. BAL fluid
samples were collected from right- and left-sided
airways, collectively pooled, and then subdivided for
the above studies. The pretherapy BAL was performed
within 2 weeks before initiation of etanercept therapy,
and the posttherapy BALwas performed within 1 week
following completion of etanercept.
Pulmonary Function Tests
For group A subjects, PFTs were performed pre-
therapy, week 4 (end of therapy), and at week 8 (post-
therapy). For group B subjects, PFTs were performed
pretherapy, then every 4 weeks during study therapy,
at week 12 (end of therapy), and week 20 (posttherapy).
In all cases, measurements of FVC, FEV1, TLC, and
DLCO were obtained using a SensorMedics Vmax
229 and SensorMedics Autobox 6200 System (Sensor-
Medics Corp., Yorba Linda, CA). Mean values for
subjects were expressed as percent predicted for indi-
viduals of the same height and age. Pretherapy PFTs
were performed within 2 weeks before the BAL, and
posttherapy PFTs were performed within 1 week of
the defined end point.
Serologic Testing
Complete blood counts, serum electrolytes, BUN,
creatinine, and liver function tests were performed at
study entry, every 4 weeks during therapy, and 4 weeks
posttherapy.
Cytokine Analysis
Blood for inflammatory cytokine analysis was
obtained at study entry and at the completion of ther-
apy for the first cohort of patients (group A). Samples
were collected in heparinized tubes, and transported to
the University of Michigan Cancer Center Immunol-
ogy Core Laboratory for processing. The plasma com-
partment was separated, divided, and stored at 280C
as per standard operating procedures, until the time of
analysis. In addition, plasma samples were obtained for
inflammatory cytokine analysis from control patients
that had signed informed consent for such sample ac-
quisition. Two subject groups served as controls for
the plasma cytokine studies: (1) SCT recipients who
had an ‘‘uncomplicated transplantation course’’
through day 100 (nine subjects), and (2) from healthy
volunteers (seven subjects). Subjects with an ‘‘uncom-
plicated transplantation course’’ received a myeloabla-
tive conditioning regimen and subsequently exhibited
no signs of aGVHD, hepatic veno-occlusive disease,
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through day 100 posthematopoietic cell transplanta-
tion and did not develop subsequent subacute lung
injury. Plasma samples were obtained on or around
day 100 posttransplantation in this group of control
subjects.
Determination of Protein Levels by ELISA
Frozen plasma samples were thawed and analyzed
in batches for a panel of inflammatory proteins includ-
ing TNF-a, TNFRI, TNFRII, sCD-14, TGF-b (Bio-
Source, Camarillo, CA), along with IL-6, IL-8, and
MCP-1 (BD BioSciences-Pharmingen, San Diego,
CA). ELISA assays were performed as per the manu-
facturer’s guidelines in the Immunology Core Labora-
tory at the University of Michigan Medical Center.
All samples and controls were run in duplicate. Limits
of detection for individual assays are as follows:
TNF-a (1 pg/mL), TNFRI (50 pg/mL), TNFRII
(100 pg/mL), sCD-14 (1 ng/mL), TGF-b (2 pg/mL),
interferon-gamma (IFN-g) (1 pg/mL), IL-8
(1 pg/mL), IL-6 (2.5 pg/mL), and MCP-1(1 pg/mL).
Etanercept Therapy
Etanercept therapy was initiated provided that
baseline BAL fluid special stains were negative and
BAL fluid cultures were negative for a minimum of
48 hours. Etanercept was reconstituted from a lyophi-
lized powder and administered subcutaneously at
a dose of 0.4 mg/kg (max dose5 25 mg), twice weekly
(72 to 96 hours between doses), for a total of eight
doses (group A) or 24 doses (group B). Dosing adjust-
ments were not made based on renal or hepatic func-
tion. No premedication was administered. Subjects
were observed for local reactions at the injection site
within 30minutes of a dose. Vital signs, including tem-
perature, blood pressure, heart rate, and respiratory
rate were recorded before, then at 15 and 30 minutes
following a dose. Group A subjects were observed in
our medical facility with every dose, whereas group B
subjects were observed for their initial one to two
doses. Etanercept therapy was discontinued and not
reinstituted, if any one of the following criteria were
subsequently met: (1) cultures, special stains, or poly-
merase chain reaction analysis of BAL fluid, blood,
or biopsy specimens became positive for a potentially
infectious organism; (2) the patient developed signs
and symptoms consistent with the diagnosis of sepsis
syndrome; or (3) the patient developed CMV viremia
and was believed to have active CMV disease.
Concomitant Immunosuppressive Therapy
Subjects on corticosteroids at study entry were re-
quired to continue corticosteroids without dose alter-
ation during the initial 4 weeks of etanercept therapy.
Corticosteroids could be subsequently tapered asclinically indicated. Subjects requiring an increase in
corticosteroid dosing during therapy were considered
therapy failures and taken off study at that point.
However, such patients continued to be assessed for
toxicity. Dosing adjustments for tacrolimus or cyclo-
sporine were allowed, based on measurement of serum
drug levels. Other immunosuppressive agents were to
continue throughout the study therapy, without dos-
ing adjustment, unless clinically warranted.
Response and Outcome
Response assessments were based on improvement
in pulmonary function parameters, pretherapy to post-
therapy. FVC measurements were used to assess re-
sponse in subjects with primary restrictive lung
defects, and FEV1 and FEV1/FVC ratios were used
to assess response in subjects with obstructive lung de-
fects. Changes in DLCO measurements, pre- and
posttherapy, were also examined for all subjects. In ad-
dition, interval response assessments at weeks 4 and 8
of therapy were determined for group B subjects. Re-
sponse was defined as a$10% improvement in the ab-
solute value for FEV1 (for obstructive defects) or FVC
(for restrictive defects). To be evaluable for response,
subjects must have completed$50% of scheduled eta-
nercept doses, a minimum of four doses for group A
and 12 doses for group B subjects. The primary study
endpoint was response at week 4 (group A) or week 12
(group B). Secondary response was determined by as-
sessment at week 8 (group A) or week 20 (group B).
Statistical Analysis
Overall survival (OS) from the start of study ther-
apy was estimated using Kaplan-Meier methods; sta-
tistical significance for differences in OS among
patient characteristics (obstructive or restrictive lung
defects, duration of etanercept therapy, and duration
of lung injury before study entry) was assessed with
a log-rank test. Statistical significance for differences
in proportions among subject groups was assessed
with a c2 test of association. Statistical comparisons
of plasma protein data were completed using
a Student’s t-test. Statistical significance was defined
as a P value\.05.RESULTS
Fifty-seven patients were evaluated for study ther-
apy. Of these, 23 were deemed ineligible based on the
presence of pathogens in their pretherapy BAL fluid
(20 patients), radiographic findings (one patient), or
relapsed disease (two patients). Thirty-four subjects,
ranging from 8 to 65 years in age, met eligibility crite-
ria and were treated (Table 2). The median time from
transplantation to onset of study therapy was 1,099
days (mean, 1,062 days; range, 173-2,920 days).
Table 2. Patient Demographics: Clinical Features at Study
Entry
Demographic Factor
Group A
(n 5 14)
Group B
(n 5 20)
Overall
(n 5 34)
Age (years)
Mean 36 40 39
Median 32 46 43
Range 17-52 8-65 8-65
Gender
Male 8 12 20
Female 6 8 14
Diagnosis
AML/MDS/MF 6 10 16
ALL 2 1 3
CML 1 4 5
NHL/CLL 3 3 6
Myeloma 1 1 2
Nonmalignant 1 1 2
HLA match
HLA matched 13 18 31
Mismatch 1 2 3
Cell source
PSC 8 17 25
Marrow 6 3 9
Donor type
MRD 8 14 22
URD 6 6 12
Chronic GVHD present
Yes 14 20 34
No 0 0 0
Corticosteroidsa
At study entry 14 14 28
Median dose (mg/kg/day) 0.4 0.2 0.3
Lung injury pattern
Restrictive 3 6 9
Obstructive 11 14 25
NIH Lung Function Score (LFS)b
Median 7 8 7.5
Mean 8 8 8
Range 2-11 4-12 2-12
Supplemental O2 required 1 2 3
AML indicates acute myelogenous leukemia; MDS, myelodysplasia; MF,
myelofibrosis; CML, chronic myelogenous leukemia; NHL, non-
Hodgkin lymphoma; ALL, acute lymphoblastic leukemia.
aMedian equivalent dose of prednisone.
bLFS was determined for subjects with obstructive lung disease only.
Table 3. Pulmonary Function Parameters: Pretherapy
(Groups A and B)
Group A (n 5 14) Group B (n 5 20) Overall (n 5 34)
FEV1 (%)
Median 49 52 51
Mean 47 52 50
Range 25-73 29-79 25-79
FVC (%)
Median 61 63 62
Mean 61 62 62
Range 28-92 39-86 28-92
DLCOcorr (%)
Median 65 60 61
Mean 63 59 60
Range 15-102 29-96 15-102
Values expressed as percent predicted for corresponding height and
weight (FVC and FEV1), or contemporaneously measured hemoglobin
(DLCOcorr).
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at study onset, with pretherapy pulmonary function
testing shown in Table 3. Nine subjects met the crite-
ria for restrictive pulmonary defects and 25 for ob-
structive defects at study entry. Subjects with OLD
had a mean NIH LFS of 8 (median, 7.5; range, 2-12)
at the time of enrollment. All subjects exhibited signs
or symptoms of systemic cGVHD, with diffuse cuta-
neous (22), oral mucosal (25), ocular (22), and hepatic
involvement (eight) noted. Twenty-three of 34 sub-
jects (68%) were on corticosteroid therapy at the
time of study entry, with dosing ranging from 0.03 to
1.9 mg/kg/day (mean, 0.4 mg/kg/day; median, 0.3
mg/kg/day). Concurrent immunosuppressive therapy
included calcineurin inhibitors (tacrolimus or cyclo-
sporine) alone (five), calcineurin inhibitors plus corti-
costeroids 6 mycophenolate (22), mycophenolate 6
corticosteroids (five), or sirolimus (two). Nine subjects
were receiving extracorporeal photopheresis (ECP) atthe time of study entry. Fourteen subjects were on an-
timicrobial prophylaxis (azithromycin or levofloxacin),
and 22 subjects were on antifungal prophylaxis, includ-
ing fluconazole (10), voriconazole (10), itraconazole
(one), and posaconazole (one) at study entry.
Response and Survival
Response was defined as a $10% improvement in
the absolute value for FEV1 (for obstructive defects) or
FVC (for restrictive defects). Thirty-one of 34 subjects
(91%) were evaluable for response, with three subjects
completing\50% of scheduled dosing. The primary
response assessment was made upon completion of
etanercept therapy at week 4 (group A) or week 12
(group B). Ten of 31 subjects (32%) met the primary
response criteria: four of 14 (29%) in group A and six
of 17 (35%) in group B; P5 .99. For the 10 responders,
the median response was 17.8% (mean, 19.1%; range,
11.0%-26.6%). When response was determined using
the change in % predicted value, the median improve-
ment was 8.0% (mean, 8.5%; range, 4%-16%) for
these same 10 patients. DLCO responses ($10% im-
provement) were seen in five of 31 (16%) evaluable
patients.
There was no difference in response based on the
pattern of lung dysfunction; three of nine patients
(33%) with RLD met the primary response criteria,
compared with seven of 22 (32%) with OLD; P 5
.73. There were no differences in response based on
the severity of disease at study onset. Subjects with
an FVC or FEV1\ 50% at study entry met response
criteria in five of 17 cases (29%) compared with re-
sponses in five of 14 (36%) subjects with an FVC or
FEV1 $50% at study entry; P 5 .79. Responses were
not improved even if higher baseline values were se-
lected for analysis. For example, five subjects exhibited
an FVC or FEV1. 60% at study entry, with only two
of the five (40%) meeting the response criteria.
Responses were seen in seven of 18 (39%) subjects
with subacute lung injury \24 months in duration,
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acute lung injury $24 months in duration; P 5 .59.
Age did not affect the likelihood of response. Four
of 10 (40%) patients\30 years in age responded, com-
pared with six of 21 (29%) patients $30 years in age
(P 5 .82). Likewise, there was no difference in re-
sponse based on stem cell source, with responses noted
in four of nine (44%) patients receiving marrow grafts,
compared with six of 22 (27%) patients receiving pe-
ripheral stem cells as their donor source (P 5 .60).
Ten subjects (31%)met the secondary response cri-
teria, defined by their response at week 8 (group A) or
week 20 (group B). Six (35%) group B subjects had re-
sponded by week 12, increasing to eight responses
(47%) by week 20; P 5 0.94. For both subject groups
(A and B), we were unable to assess the durability of re-
sponse at later time points, as additional modifications
in immunosuppressive therapy had been allowed.
Twenty-one of the 34 (62%) subjects enrolled
remain alive, 2.5 to 9.6 years status posttherapy. Esti-
mated 5-year survival from study entry was 61%
(95% confidence interval [CI], 46%-80%) for all sub-
jects. Estimated 5-year survival rates for subjects
treated on group A and group B therapy were 64%
and 56%, respectively (P5 .70) (Figure 2A). Likewise,
5-year survival estimates for subjects treated with RLD
was 44%, compared with 67% for those treated for
OLD (P 5 .19) (Figure 2B). Among the 31 patients
who completed therapy, 5-year survival estimates
were 90% (95% CI, 73%-100%) for 10 patients who
responded to therapy, compared with 55% (95% CI,
37%-83%) for the 21 patients that failed to meet re-
sponse criteria; P 5 .07 (Figure 2C).Responders (n=10)
non-Responders (n=21)
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Figure 2. (A) OS by duration of etanercept therapy, group A (4 weeks)
versus group B (12 weeks). Group A (—). Group B (- - -). (B) OS by pat-
tern of lung injury, obstructive (—) versus restrictive (- - -) defects. (C)
OS by response to therapy, responders (—) versus nonresponders (- - -).Toxicity
Etanercept dosing was well tolerated, with therapy
completed in all 14 patients in group A and 17 of
20 group B subjects (Table 4). No infusion-related
reactions (fever, blood pressure changes) or local site
injection reactions were reported following the ad-
ministration of etanercept. Grade 3 to 4 infectious
complications occurred in five subjects, including mu-
cormycosis pneumonia (one), aspergillus pneumonia
(one), acute sinusitis (one), osteomyelitis (one), and
a grade 3 fever without an identified source (one).
No episodes of bacteremia or viremia were noted dur-
ing study therapy. Posttherapy BAL was performed in
28 of the 34 cases. Only twice were potential
pathogens—Aspergillus species (one), mucormycosis
(one)—identified on posttherapy BAL fluid cultures.
Osteomyelitis was noted within the first week of ther-
apy in one patient and was felt to be unlikely related to
study treatment. Hematologic toxicity was rare, with
one group B subject developing a transient grade 3
thrombocytopenia. Two toxic deaths occurred while
on study therapy, from progressive pulmonary dys-function (one) and mucormycosis pneumonia (one).
Two subjects died from relapse, the relapses occurring
within 4 weeks following initiation of study therapy.
Table 4. Grade 3 to 4 Toxicities (CTC v.3.0)
Incidence (%)
Infection 5 (14)
Electrolyte 4 (11)
Hyperglycemia 3 (8)
Renal/GU 2 (6)
Hepatic (ALT, T.Bili) 2 (6)
Pain 2 (6)
Hypertension 1 (3)
Gastrointestinal 1 (3)
Central nervous system 1 (3)
Thrombocytopenia 1 (3)
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The study was not designed to evaluate responses
in other organ sites. However, corticosteroid dosing
at study onset and completion was analyzed. Eleven
of 31 evaluable subjects (35%) had a $10% reduction
in corticosteroid dosing during study therapy. Five of
14 (36%) group A subjects had reductions in cortico-
steroid dosing, compared with six of 17 (35%) evalu-
able group B subjects. No change in corticosteroid
dosing was made in 17 patients, and three subjects
(all in group A) required an increase in corticosteroids
while receiving etanercept therapy.Plasma Cytokine Levels
Plasma samples were collected at study entry from
all group A subjects, with subsequent protein levelsIIRFNT TN
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Figure 3. Plasma samples were collected, and protein levels were analyzed
Materials and Methods. In addition, control plasma samples were collected at d
tation recipients without complications (Control [BMT]) and from healthy (noanalyzed and compared with transplantation controls
(allogeneic SCT recipients without complications)
and from healthy (nontransplantation) controls as
described in Materials and Methods. As shown in
Figure 3, subjects with RLD orOLD showed increases
in plasma levels of some, but not all proteins evaluated,
including sTNFRI, sTNFRII, IL-8, and TGF-b.
Posttherapy plasma levels were not appreciably
changed, other than the expected increase in sTNFRII
levels associated with systemic etanercept administra-
tion (data not shown). Plasma levels for IL-6 and
TNF-a were at the limit of detection and not different
among groups (data not shown).Ineligible Patients
As previously noted, 20 patients were enrolled but
deemed ineligible for study therapy because of the
presence of pathogens on their prestudy BAL. In all
20 cases, the subjects had no clinical signs of an acute
infectious pneumonitis, with absence of fever, pleuritic
chest pain, or other acute symptomatology at the time
of enrollment. Occult fungal infections were noted in
13 of the 20 patients, including Aspergillus species (10),
mucormycosis (one), C. krusei (one), and Cryptococcus neo-
formans (one). Other occult infections included Gram-
negative bacteria (five), and mycobacteria (three), with
mycobacteria noted concurrently with Aspergillus in
one case. All 20 patients were treated for the identified41DCsFRI
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nary complications noted within 2 months of initiating
antimicrobial therapy. In the remaining 17 patients,
PFTs were obtained 6 to 12 months following initia-
tion of antimicrobial therapy, with the target PFT
parameter (FEV1 or FVC) improving in only five of
17 patients. The remaining 12 patients all had a
decline in their target PFT parameter despite antimi-
crobial therapy (median change, 217.4%; range,
22.0% to 236.8%).DISCUSSION
Our study reports the use of a solubleTNF binding
agent, etanercept, in the management of 34 allogeneic
SCTrecipientswith subacute lung injury.The response
rates seen in our trial were promising, given that the de-
gree of pulmonary dysfunction observed in subjects at
the time of study entry was severe, with a mean LFS
of 8, a median FEV1 51% in patients with OLD, and
a median FVC 62% in subjects with RLD. There are
few ‘‘prospective’’ trials reported in the treatment of
subacute lung injury post-SCT,with themajority of tri-
als either retrospective in nature, anecdotal case series,
utilizing variable response definitions, or focusing on
disease stabilization rather than improvement. The
potential benefits of systemic corticosteroids, inhaled
corticosteroids, immunosuppressive therapy, broncho-
dilators, antimicrobial prophylaxis (azithromycin),
anti-TNF antibody therapy (infliximab), ECP, and leu-
kotriene inhibitors have all been examined in small
studies (\15 patients), with objective responses ranging
from 8% to 100% [42-49]. Even the role of etanercept
in treating subacute lung injury post-SCThas been pre-
viously described, with three of four treated patients
showing improvements in DLCO or subjective clinical
responses [40]. Given the strict methodology and re-
sponse definitions used in our study, our 32% response
ratemay serve as a benchmark for future clinical trials in
this group of patients.
OS rates were likewise promising in our study,
with estimated 5-year survival rates of 61% for all sub-
jects and 90% for those responding to therapy. By
comparison, Dudek [42] noted a 5-year posttransplan-
tation survival rate of 10% among patients with BOS,
with a 79% 5-year survival rate (post-BOS) for those
responding to front-line therapy and 13% for those
failing. Clark et al [11,14] reported a 35% survival
rate within 3 years of diagnosis of BOS, with long-
term survival rates ranging from 0% to 86% noted in
other reports.
A major finding of this report is that the use of
etanercept in heavily immune-suppressed transplanta-
tion recipients was not associated with significant in-
fectious or noninfectious complications. Overall, the
toxicity of etanercept therapy was minimal. Histori-
cally, etanercept has been associated with infectiousrisks in patients with other inflammatory conditions,
including Crohn’s disease, rheumatoid arthritis, and
psoriaris, and has been contraindicated in patients
with sepsis syndrome [50-53]. Reactivation of latent
hepatitis B, hepatitis C, and tuberculosis infections
has been seen with prolonged etanercept usage in
these patient populations [54-57]. Despite the
intensity of immune suppression concurrently used in
our study population, secondary infections were ex-
tremely rare during or following etanercept therapy.
No other major noninfectious complications were
noted. Two patients relapsed early while on study,
within 1 and 4 weeks of study entry. The impact of
the etanercept on these two relapses is not clear. The
potential for TNF inhibitors to negatively affect the
graft-versus-leukemia (GVL) effect of the donor graft
has been speculated with infliximab but not reported
with etanercept [58]. Whereas anti-TNF monoclonal
antibodies such as infliximab bind both soluble and
membrane-bound TNF, etanercept binds strictly to
soluble TNF, theoretically decreasing its potential
impact on GVL activity.
As noted, both RLD and OLD may contribute to
significant morbidity and late mortality in allogeneic
SCT recipients [14,16,17,21,23,59]. In each scenario,
collagen deposition and the development of fibrosis
either in the interstitial (RLD) or peribronchiolar
space (OLD) are believed to contribute to the
patterns of lung dysfunction displayed on pulmonary
function testing. It has been hypothesized that OLD
and RLD after allogeneic SCT likely result from an
initial insult to lung parenchyma, followed by an
ongoing dysregulated reparative process involving
the interplay between recruited immune effector cells
and the resident cells of the pulmonary vascular
endothelium and interstitium. To this end, we have
previously proposed a triphasic model of chronic, non-
infectious lung injury after allogeneic SCT that in-
volves early evidence for T cell activation, leukocyte
recruitment, inflammatory cytokine release, and ulti-
mately, the deposition of collagen and the develop-
ment of fibrosis [24]. In this model, an allogeneic
response initiates injury to lung epithelial cells that is
followed by a dysregulated reparative response and
scarring of either the terminal airways as in OLD or
in the case of RLD, the interstitial space.
Preliminary data generated in this study showed
that patients with OLD and RLD had increased
plasma levels of inflammatory markers including
sTNFRI, sTNFRII, IL-8, and TGF-b. A more de-
tailed biomarker analyses of plasma and BAL fluid col-
lected from the entire study population is in progress
and should help to validate our preliminary findings
and further illuminate immunologic mechanisms that
may be operative in the development of chronic pul-
monary dysfunction after SCT. In general, the factors
that regulate the progression from acute to chronic
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remain to be determined, but experimental data sug-
gest that TNF-a may be a common thread during
this transition. Our group has previously reported
that TNF-a is an important mediator of acute lung in-
jury after allogeneic SCT [18,19]. Moreover, TNF-a
directly contributes to the development of interstitial
fibrosis in several non-SCT models [60-62], and
abrogation of TNF-a signaling either by antibody
neutralization or by using mutant mice deficient
in both TNF receptors significantly reduces lung
fibrosis [30,63]. Additional evidence for a role of
TNF-a in the transition from acute to chronic lung
injury comes from studies using transgenic rodents
with targeted overexpression of TNF-a in the lungs
[61,62]. In these studies, early histopathology
included a lymphocytic infiltrate similar to that seen
in experimental IPS models, whereas the histologic
changes associated with more prolonged exposure
to TNF-a include collagen deposition and the
development of fibrosis. From a clinical standpoint,
Raghu and colleagues [64] recently completed an ex-
ploratory placebo-controlled trial using etanercept in
88 subjectswith idiopathic pulmonary fibrosis.Overall,
treatment with etanercept was well tolerated. Although
there were no differences in the predefined endpoints,
a decreased rate of disease progression was seen in
several physiologic, functional, and quality-of-life end-
points among subjects receiving etanercept for idio-
pathic pulmonary fibrosis.
Recent biomarker studies in patients with cGVHD
additionally support a hypothesis that Th1 and Th2
cytokine production may play a role in the pathogene-
sis of the disorder [65]. Increased levels of Th1
cytokines, including IFN-g, TNF-a, IL-1, and IL-6
have been noted in skin and renal biopsies and in pe-
ripheral blood lymphocytes collected from patients
with cGVHD [65-67]. In addition, elevations in
plasma cytokine levels, including TNF-a, have been
shown to precede the clinical development of
cGVHD [65,68]. Elevated levels of macrophage
migration inhibitory factor, an important regulator
of TNF-a production, have also been noted in
patients with cGVHD [69], and reductions in plasma
levels of TNF-a have been reported following ECP
therapy for cGVHD [70]. A recent Children’s Oncol-
ogy Group study reported increased plasma levels
of T and B cell activation markers, including sBAFF,
anti-dsDNA antibody, sIL-2R, and sCD13 in
patients with early- and late-onset cGVHD [71]. Fi-
nally, clinical studies have uncovered a possible link
between variations in genes encoding for components
of the innate immune system that exist within donor-
recipient pairs and the development of air-flow ob-
struction and BOS following allogeneic SCT [72,73].
There are a few limitations to this study that war-
rant comment. One could argue that current NIHconsensus criteria for BOS [41] were not used to deter-
mine study eligibility for all 25 patients with OLD.
The definition for OLD in the current trial predated
the NIH consensus criteria, with the majority of pa-
tients (69%) enrolling before the NIH consensus pub-
lication. However, when NIH consensus criteria were
applied, 22 of 25 (88%) patients with OLD in our
study still met the diagnostic criteria for BOS, based
on PFT results, radiographic findings, and negative
BAL cultures/stains. The remaining three subjects
met three of the four diagnostic criteria for BOS, nar-
rowly failing to achieve the requisite FEV1/FVC ratio
\0.7 by 0.01-0.03, respectively. Our study require-
ment for a negative pretherapy BAL additionally indi-
cates how strict we were in selecting our patients.
Second, although response rates and survival curves
in our study population are encouraging, comparisons
can only be made to previously published reports. This
was no placebo-controlled study nor was there a con-
temporary group of patients with subacute lung injury
(treated with standard immunosuppression) available
at the University of Michigan for comparison.
It is interesting to note that although 57 patients
were enrolled on study, 20 (35%) were ineligible to
begin study therapy because of the identification of
pathogens on pretherapy BAL fluid cultures. The high
incidence of occult infections (primarily fungal) in
this study population indicates the need for bronchos-
copy as a routine management tool in the evaluation
of allogeneic SCT recipients with subacute lung dys-
function. In the majority of cases, the underlying pul-
monary function defect (obstructive or restrictive)
persisted following completion of appropriate antimi-
crobial therapy.
In summary, the current study was a prospective,
open-label trial for patients with late-onset (subacute)
lung injury following allogeneic SCT. The use of
etanercept therapy was well tolerated in this patient
population, with few complications observed and
objective responses seen in 32% of patients. Long-
term survival following etanercept therapy was excel-
lent, with an estimated 5-year OS of 67% for patients
with obstructive pulmonary disease, and 90% for those
responding to 4 or 12 weeks of therapy. The response
rates and toxicity profile support the development of
larger phase II or randomized phase III trials to inves-
tigate the role of etanercept therapy in patients with
subacute lung injury postallogeneic SCT.ACKNOWLEDGMENTS
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